arrow_back Trending Legislation
Share share

Congress blocks strict FDA oversight of laboratory developed diagnostic tests.

This resolution aims to nullify a new Food and Drug Administration (FDA) rule that would have imposed strict federal oversight on specialized diagnostic tests developed within laboratories (LDTs). If the resolution passes, these tests will remain exempt from the new, rigorous federal requirements. This means the availability and costs of many personalized diagnostic tests will not be immediately affected by the new FDA regulations.
Key points
Halting FDA plans to treat Laboratory Developed Tests (LDTs) as traditional medical devices subject to strict control.
Diagnostic tests developed by laboratories (e.g., personalized genetic testing) will remain outside new, strict federal regulations for now, potentially impacting their availability and innovation.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Print number: SJRES 82
Sponsor: Sen. Paul, Rand [R-KY]
Process start date: 2024-05-15
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Congress blocks strict FDA oversight of laboratory developed diagnostic tests.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is SJRES 82.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-05-15.

What are the main provisions?

Key points include:

  • Halting FDA plans to treat Laboratory Developed Tests (LDTs) as traditional medical devices subject to strict control.
  • Diagnostic tests developed by laboratories (e.g., personalized genetic testing) will remain outside new, strict federal regulations for now, potentially impacting their availability and innovation.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Paul, Rand [R-KY].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

Analysis and Potential Impact of SJRES 82

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health